

Antiepileptic drugs

S

Lack of efficacy: 9 case reports

A study of 252 patients, who had been followed-up for at least 1 year between 1 July 2019 and 31 December 2021, described 9 patients [2 males and 7 females; *exact ages not stated*]; they experienced a lack of efficacy with carbamazepine, gabapentin, lacosamide, lamotrigine, levetiracetam or topiramate for the treatment of epilepsy.

The patients, who had been diagnosed with focal, generalised or mixed epilepsy at the age of 1–30 years, subsequently started receiving carbamazepine and levetiracetam (1 patient), levetiracetam and lacosamide (1 patient), lacosamide and gabapentin (1 patient), levetiracetam, lacosamide and topiramate (1 patient), lamotrigine (1 patient), carbamazepine (1 patient) and levetiracetam [3 patients; *routes and dosages not stated*]. However, all patients were found to have drug-resistant epilepsy (i.e. lack of efficacy). Later, at 19–39 years of age, all patients developed COVID-19 infection [*aetiologies not specified*].

Bosak M, et al. COVID-19 among patients with epilepsy: Risk factors and course of the disease. *Epilepsy and Behavior* 120: 107996, Jul 2021. Available from: URL: <http://www.elsevier.com/inca/publications/store/6/2/2/8/2/2/index.htm>

803575388